Elanco Animal Health, Inc. (ELAN)

Elanco Animal Health's stock (ELAN) has experienced significant movement over the past six months, increasing by 167.48% over the last 12 months. As of April 11, 2026, the stock traded at $23.11, with a 52-week range between $8.02 and $27.72. On February 24, 2026, Elanco reported Q4 2025 revenue of $1.14 billion and adjusted EPS of $0.13, surpassing analysts' estimates, leading to a 6.6% stock gain. Elanco provided guidance for Q1 2026, expecting EPS between $0.33 and $0.36, and projected full-year 2026 earnings between $1.00 and $1.06 per share. The company's net leverage ratio was 3.6x adjusted EBITDA as of December 31, 2025.

The demand for many of Elanco's products can experience regional and seasonal fluctuations, influenced by weather conditions and pest pressures. In 2024, approximately 70% of the total revenue for Seresto and 55% for the Advantage Family was generated in the first half of the year. Seasonal climate shifts can impact conditions in poultry houses, leading to fluctuations in the risk of diseases like coccidiosis, necessitating seasonal programs for intestinal health management.

Elanco Animal Health, Inc. is an American pharmaceutical company that innovates, develops, manufactures, and markets products for pets and farm animals. It is the third-largest animal health company globally, with a diverse portfolio marketed under approximately 200 brands. Elanco's products for pets include parasiticides, vaccines, and therapeutics, such as Seresto, Credelio, and Interceptor Plus. For farm animals, products focus on efficiency, disease prevention, food safety, and sustainability, including Bovaer and Experior.

Elanco Animal Health supplies its products and services to farmers, veterinarians, and pet owners in more than 90 countries worldwide. The company's global headquarters is located in Indianapolis, Indiana, U.S. Elanco is restructuring its global operations, shifting investment towards the U.S. and consolidating its overseas footprint, including closing its German animal health R&D facility and redirecting capital towards its Innovation Laboratories in Indiana.

In the past year, Elanco has focused on advancing its purpose and impact, releasing its 2024 Impact Report in June 2025. Achievements include increasing pet owner access to parasite protection, ranking as the #1 retail parasiticide dispenser in the U.S., and expanding global retail offerings. The company also advanced livestock sustainability with FDA approval for Experior use in finishing heifers and enrolled 11% of the U.S. dairy herd into its UpLook database. Elanco committed $310,000 in scholarships for veterinary science students and served as an inaugural signatory to the U.S. Animal Research Openness Agreement (USARO). A 2022 report linked Elanco's Seresto flea and tick collar to incidents of pesticide poisoning, including pet deaths.

Elanco Animal Health Incorporated has a widely dispersed ownership structure, with a significant portion held by institutional investors. As of April 9, 2026, there were 486 institutional owners and shareholders holding a total of 501,322,396 shares, representing nearly 97.5% of Elanco's stock. Major institutional owners include Dodge & Cox, Fmr Llc, Vanguard Group Inc, and BlackRock, Inc.